EDISON, N.J.—GMP-certified palm tocotrienol supplier Carotech will exhibit at SupplySide West Global Expo and Conference 2014 and share latest research development of its Non-GMO Project-verified clinical ingredient Tocomin SupraBio®.
A recent clinical trial published by UK and Malaysian researchers in the American Heart Association’s journal of STROKE reported that Tocomin SupraBio® supplementation attenuated the development of white matter lesions (an independent prognostic measure of future stroke risk) in human brain.
Another group of researchers in Malaysia and the Philippines independently showed in human studies that Tocomin SupraBio® supplementation improved liver echogenic response in patients with non-alcoholic fatty liver disease (NAFLD), and that lifestyle modification and exercise together with supplementation Tocomin SupraBio® is nearly four-times more effective in improving liver stiffness in NAFLD patients, compared to lifestyle modification and exercise alone.
Researchers at University of Florida and University of Nebraska recently discovered a new health benefit of tocotrienols in inhibiting adipose inflammation and attenuating high fat diet-induced obesity, as well as improved glucose tolerance, insulin sensitivity and reduced inflammation in adipose tissue, through both in vitro and in vivo studies. This is an exciting discovery for tocotrienols in addressing obesity related conditions.
“Significant breakthrough in Tocomin SupraBio® research in the brain and liver health areas confirm decades of anecdotal findings," said said Bryan See, Carotech’s regional product manager. “This is an exciting era for tocotrienols."
Visit Carotech Inc. at booth 22136 at SupplySide West, Mandalay Bay Convention Resort, Las Vegas, on Oct. 8 to 9.